Max-Planck-Institut für Psychiatrie Krankenhaus für Psychiatrie

What Max-Planck-Institut für Psychiatrie Krankenhaus für Psychiatrie does

Max-Planck-Institut für Psychiatrie Krankenhaus für Psychiatrie (the Max Planck Institute of Psychiatry) is a research institute and licensed psychiatric hospital located in München-Schwabing-West, Germany, operating under the Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Founded in 1926, the institute combines a basic-research program in neuroscience and psychiatric disorders with a clinical operation that delivers outpatient, day-clinic, and inpatient psychiatric care, primarily for stress-related disorders including depression and anxiety. Research activities focus on biomarker discovery, synapse biology relevant to schizophrenia, immunological mechanisms differentiating depression from psychosis, and stress-protein mechanisms linked to childhood-trauma outcomes, with the stated objective of translating findings rapidly into personalized therapies and prevention approaches.

The institute's product portfolio comprises clinical services (Ambulanzen, Tagkliniken, Stationen), diagnostics, therapy offerings, expert assessments, clinical studies and trials, and a basic-research program, alongside the IMPRS-TP (International Max Planck Research School for Translational Psychiatry) PhD and integrated residency program. Distribution is regional within Germany, with patients acquired via physician referrals, self-referrals, and clinical-study enrollment. Revenue mechanics operate within the German statutory (GKV) and private health-insurance frameworks, supplemented by institutional federal-state funding channeled through the Max Planck Society; pricing is not publicly disclosed, and there are no venture or private-equity funding rounds on record. The institute also runs a multi-channel public outreach program via its website, press activities, scientific seminars, public lectures, and social media (Instagram, LinkedIn, Facebook, YouTube, Bluesky).

Name

Max-Planck-Institut für Psychiatrie Krankenhaus für Psychiatrie

Legal name

Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

Website

https://mpipsykl.mpg.de

Company type

Private

Founded year

1926

Operating status

Operating

Headcount range

11–50 employees

Short description

The Max Planck Institute of Psychiatry is a Munich-based non-profit research institute and psychiatric hospital under the Max Planck Society, combining basic neuroscience research on depression, anxiety, and stress-related disorders with outpatient, day-clinic, and inpatient psychiatric care within Germany's statutory health insurance framework.

Ownership category

akta.pro rank

Product category

Psychiatric Hospital and Translational Psychiatry Research

NAICS

Psychiatric and Substance Abuse Hospitals (622210), Outpatient Mental Health and Substance Abuse Centers (621420)

SIC

Services-Health Services (8000), Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Inpatient Psychiatric Hospitals & Units (HLAFACAB)

akta.pro secondary industries

Outpatient Mental Health & Counseling Clinics (HLAFABAC), Residential Mental Health Treatment Centers (HLAFACAC)

Keywords

• Psychiatric hospital services
• Translational psychiatry research
• Stress-related disorder treatment
• Mental health diagnostics
• Neuroscience clinical trials

Headquarters

HQ city

Munich

HQ country

Germany

HQ region

Europe

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Infrastructure, Others

Distribution channels5 records

Marketing channels8 records

Core offering

The Max Planck Institute of Psychiatry operates as a research clinic (Forschungsklinik) that combines clinical psychiatric treatment with basic and translational scientific research. It provides specialized care for stress-related disorders such as depression, anxiety disorders, and schizophrenia through outpatient clinics (Ambulanzen), day clinics (Tagkliniken), and inpatient wards (Stationen), while conducting research on causes of psychiatric disorders to develop personalized therapies and prevention approaches. The institute also runs clinical trials, diagnostic services, therapy programs, and the IMPRS-TP graduate school for doctoral and physician training in translational psychiatry.

Product overview

Max Planck Institut für Psychiatrie is a research clinic (Forschungsklinik) that combines clinical treatment services with scientific research. The institution offers a unified portfolio of psychiatric care including outpatient clinics (Ambulanzen), day clinics (Tagkliniken), inpatient wards (Stationen), diagnostic services, therapy offerings, and clinical studies. Research activities focus on stress-related disorders including depression and anxiety, with the stated goal of translating scientific findings rapidly to patient care. The institution also operates the IMPRS-TP graduate school for doctoral training in psychiatric research.

Differentiator

Problem solved

Functional benefit

Products and services

• Klinik (Clinical Services) Clinical treatment services for stress-related psychiatric disorders including depression and anxiety, delivered as a research clinic that provides rapid access to scientific findings for patients.
• Ambulanzen (Outpatient Clinics) Specialized outpatient clinic services providing psychiatric treatment and care for patients with stress-related and other psychiatric disorders.
• Tagkliniken (Day Clinics) Day treatment programs for psychiatric patients requiring structured therapeutic interventions without overnight stays.
• Stationen (Inpatient Wards) Inpatient psychiatric treatment facilities providing comprehensive care for patients requiring hospitalization for psychiatric conditions.
• Therapieangebote (Therapy Services) Range of therapeutic interventions for psychiatric conditions including evidence-based treatments for patients seeking specialized psychiatric care.
• Diagnostik (Diagnostics) Diagnostic services for psychiatric conditions including clinical assessments and testing for patients and referring physicians.
• Klinische Studien (Clinical Studies) Research studies and clinical trials conducted at the institute for developing new psychiatric treatments, with patient and proband participation.
• Forschung (Research) Basic and translational research into the causes of psychiatric disorders to develop better, personalized therapies and prevention approaches.
• IMPRS-TP (International Max Planck Research School for Translational Psychiatry) PhD program for internationally outstanding students in molecular, cellular, and systemic psychiatric research, plus an integrated doctoral/residency program for young physicians.

Quantifiable outcome

• Rapid translation of research findings to clinical patient care due to integrated research clinic model

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Max-Planck-GesellschaftcoreStrategic or Co-development PartnerThe Max Planck Institute of Psychiatry is part of the Max Planck Society (Max-Planck-Gesellschaft), one of Germany's leading research organizations. This affiliation provides institutional governance, funding support, and integration into a network of over 80 Max Planck Institutes conducting basic research.

Recent moves5 records

Expansion highlights5 records

Direct peers

• King's College London - Institute of Psychiatry, Psychology & Neuroscience (IoPPN): One of the world's largest and most cited psychiatric research institutions. Comparable in combining clinical psychiatric services with fundamental neuroscience, biomarker, and translational psychiatry research.
• University Hospital Heidelberg - Department of Psychiatry: Major German university psychiatric hospital with translational research programs on depression, schizophrenia, and biomarkers. Competes with MPIP for talent, grants, and clinical-trial enrollment in the German market.
• McLean Hospital (Harvard Medical School affiliate): US psychiatric hospital with deep research affiliation (Harvard), combining inpatient psychiatric care with neuroscience and biomarker research on depression, anxiety, and schizophrenia — structurally similar to MPIP's Forschungsklinik model.
• Charité - Universitätsmedizin Berlin (Department of Psychiatry and Psychotherapy): Europe's largest university hospital with a major psychiatric research department. Comparable as a combined clinical-research psychiatric institution, with broader multi-site footprint and significantly larger headcount than MPIP.
• Central Institute of Mental Health (ZI Mannheim): German research hospital combining psychiatric and addiction treatment with translational neuroscience research. Closest structural analog to MPIP: state-funded, combined clinical-research mandate, focus on stress-related disorders and biomarker development.

Emerging players

• Leibniz Institute for Resilience Research (LIR): German Leibniz-affiliated research institute focused on stress, resilience, and stress-related disorders including depression. More focused than MPIP on resilience biology but overlapping research themes and German public-funding structure.

Regional players

• Karolinska Institutet - Department of Neuroscience: Swedish academic medical center with strong psychiatric and neuroscience research, including translational work on mood and stress-related disorders. Comparable research focus but different national funding context.
• Psychiatric University Hospital Zurich (Burghölzli): Swiss psychiatric university hospital combining inpatient care with research on depression, anxiety, and schizophrenia. Structurally comparable to MPIP but serves a different national catchment.

Broad incumbents

• National Institute of Mental Health (NIMH): US federal agency for mental health research, including intramural clinical-research programs. Comparable research mission on stress-related disorders and biomarkers, but US federal funding model and significantly larger scale than MPIP.

Others

• Max Planck Institute of Psychiatry - sibling Max Planck institutes (e.g., MPI for Biology of Ageing, MPI for Neurobiology): Sibling Max Planck Society institutes providing shared governance, funding access, and scientific exchange. Comparable funding model and institutional brand, but with different (often non-clinical) research focuses such as neurobiology, cognition, and aging.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UChzU2jE-vOBDkS9pSAi6WYg
• Facebookfacebook.com/MPIPsychiatrie
• LinkedInlinkedin.com/company/max-planck-institut-f%C3%BCr-psychiatrie-krankenhaus-f%C3%BCr-psychiatrie
• Instagraminstagram.com/mpi_psychiatry

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Max-Planck-Institut für Psychiatrie Krankenhaus für Psychiatrie